Cardiovascular Toxicities of Small Molecule Tyrosine Kinase Inhibitors: An Opportunity for Systems-Based Approaches

S. A. Brown, L. Nhola, Joerg Herrmann

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Once universally considered a rapidly fatal condition, cancer has increasingly become a chronic medical condition and comorbidities and adverse effects of cancer therapies have become increasingly significant. One of the leading advancements that has gained traction for the treatment of a variety of malignancies is the class of small molecule tyrosine kinase inhibitors (TKIs). Although, in many aspects revolutionary, TKIs have their own profile of side effects, including cardiovascular side effects, the most common being hypertension (HTN), congestive heart failure, corrected QT (QTc) prolongation, and instances of premature coronary heart disease. Herein, we describe the mechanisms of small TKI-induced cardiovascular toxicity and related intracellular signaling. In particular, systems-based approaches to the understanding of small TKI-induced cardiovascular toxicity are addressed. The pathophysiology of synergic cardiovascular toxicity from TKIs, anthracyclines, and monoclonal antibodies (e.g., trastuzumab, bevacizumab) is illustrated. Finally, recommendations are made for implementing systems medicine in clinical practice, for individualized cardiovascular wellness after cancer therapy.

Original languageEnglish (US)
Pages (from-to)65-80
Number of pages16
JournalClinical Pharmacology and Therapeutics
Volume101
Issue number1
DOIs
StatePublished - Jan 1 2017

Fingerprint

Protein-Tyrosine Kinases
Neoplasms
Anthracyclines
Traction
Systems Analysis
Coronary Disease
Comorbidity
Therapeutics
Heart Failure
Monoclonal Antibodies
Hypertension

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Cardiovascular Toxicities of Small Molecule Tyrosine Kinase Inhibitors : An Opportunity for Systems-Based Approaches. / Brown, S. A.; Nhola, L.; Herrmann, Joerg.

In: Clinical Pharmacology and Therapeutics, Vol. 101, No. 1, 01.01.2017, p. 65-80.

Research output: Contribution to journalArticle

@article{f0ab834021854e0ea1d51a2f13d2a4a3,
title = "Cardiovascular Toxicities of Small Molecule Tyrosine Kinase Inhibitors: An Opportunity for Systems-Based Approaches",
abstract = "Once universally considered a rapidly fatal condition, cancer has increasingly become a chronic medical condition and comorbidities and adverse effects of cancer therapies have become increasingly significant. One of the leading advancements that has gained traction for the treatment of a variety of malignancies is the class of small molecule tyrosine kinase inhibitors (TKIs). Although, in many aspects revolutionary, TKIs have their own profile of side effects, including cardiovascular side effects, the most common being hypertension (HTN), congestive heart failure, corrected QT (QTc) prolongation, and instances of premature coronary heart disease. Herein, we describe the mechanisms of small TKI-induced cardiovascular toxicity and related intracellular signaling. In particular, systems-based approaches to the understanding of small TKI-induced cardiovascular toxicity are addressed. The pathophysiology of synergic cardiovascular toxicity from TKIs, anthracyclines, and monoclonal antibodies (e.g., trastuzumab, bevacizumab) is illustrated. Finally, recommendations are made for implementing systems medicine in clinical practice, for individualized cardiovascular wellness after cancer therapy.",
author = "Brown, {S. A.} and L. Nhola and Joerg Herrmann",
year = "2017",
month = "1",
day = "1",
doi = "10.1002/cpt.552",
language = "English (US)",
volume = "101",
pages = "65--80",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Cardiovascular Toxicities of Small Molecule Tyrosine Kinase Inhibitors

T2 - An Opportunity for Systems-Based Approaches

AU - Brown, S. A.

AU - Nhola, L.

AU - Herrmann, Joerg

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Once universally considered a rapidly fatal condition, cancer has increasingly become a chronic medical condition and comorbidities and adverse effects of cancer therapies have become increasingly significant. One of the leading advancements that has gained traction for the treatment of a variety of malignancies is the class of small molecule tyrosine kinase inhibitors (TKIs). Although, in many aspects revolutionary, TKIs have their own profile of side effects, including cardiovascular side effects, the most common being hypertension (HTN), congestive heart failure, corrected QT (QTc) prolongation, and instances of premature coronary heart disease. Herein, we describe the mechanisms of small TKI-induced cardiovascular toxicity and related intracellular signaling. In particular, systems-based approaches to the understanding of small TKI-induced cardiovascular toxicity are addressed. The pathophysiology of synergic cardiovascular toxicity from TKIs, anthracyclines, and monoclonal antibodies (e.g., trastuzumab, bevacizumab) is illustrated. Finally, recommendations are made for implementing systems medicine in clinical practice, for individualized cardiovascular wellness after cancer therapy.

AB - Once universally considered a rapidly fatal condition, cancer has increasingly become a chronic medical condition and comorbidities and adverse effects of cancer therapies have become increasingly significant. One of the leading advancements that has gained traction for the treatment of a variety of malignancies is the class of small molecule tyrosine kinase inhibitors (TKIs). Although, in many aspects revolutionary, TKIs have their own profile of side effects, including cardiovascular side effects, the most common being hypertension (HTN), congestive heart failure, corrected QT (QTc) prolongation, and instances of premature coronary heart disease. Herein, we describe the mechanisms of small TKI-induced cardiovascular toxicity and related intracellular signaling. In particular, systems-based approaches to the understanding of small TKI-induced cardiovascular toxicity are addressed. The pathophysiology of synergic cardiovascular toxicity from TKIs, anthracyclines, and monoclonal antibodies (e.g., trastuzumab, bevacizumab) is illustrated. Finally, recommendations are made for implementing systems medicine in clinical practice, for individualized cardiovascular wellness after cancer therapy.

UR - http://www.scopus.com/inward/record.url?scp=85002952570&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85002952570&partnerID=8YFLogxK

U2 - 10.1002/cpt.552

DO - 10.1002/cpt.552

M3 - Article

C2 - 27806435

AN - SCOPUS:85002952570

VL - 101

SP - 65

EP - 80

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 1

ER -